Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance

Clinical and Applied Thrombosis/Hemostasis

Volumn 11, Issue 4, 2005, Pages 429-434

  Kanazawa, Shigenori ^a   Yamaguchi, Kazuyuki ^a   Kinoshita, Yoshimi ^b   Muramatsu, Mikiko ^a   Komiyama, Yutaka ^a   Nomura, Shosaku ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b Kitano Hospital   (Japan)

Author keywords

EGFR; Erb; Hemoptysis; Platelet; Prostanoid; ZD1839

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ADENOSINE DIPHOSPHATE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; GEFITINIB; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTANOID; THROMBOXANE; THROMBOXANE A2; THROMBOXANE B2;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL FUNCTION; CANCER GROWTH; CANCER PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; FEMALE; HEMOPTYSIS; HUMAN; LUNG CANCER; LUNG DISEASE; MALE; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; BLOOD VESSELS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PROSTAGLANDINS; QUINAZOLINES;

EID: 27544499208     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960501100409     Document Type: Article

References (27)

1. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958.
2. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241.
3. Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional randomized phase trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237.
4. Okamoto I, Fujii K, Matsumoto M, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 2003;40:339.
5. Ieki R, Saitoh E, Hashimoto E, et al. Alveolar hemorrhage as a possible adverse drug reaction by gefitinib. Gan To Kagaku Ryoho 2003;30:977.
6. Turini ME, DuBois RN. Cyclooxygenase-2: A therapeutic target. Annu Rev Med 2002;53:35.
7. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429.
8. Rudnick DA, Perlmutter DH, Muglia LJ. Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc Natl Acad Sci USA 2001;98:8885.
9. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064.
10. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861.
11. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306.
12. Tortora G, Caputo R, Damiano V, et al. Combination of a selective Cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase an antisense cause cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003;9:1566.
13. Wells A. Molecules in focus EGFR receptor. Int J Biochem Cell Biol 1999;31:637.
14. Perry JE, Grossman ME, Tindall DJ. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate 1998;35:117.
15. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs 2000;59:753.
16. Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: A systematic review with meta-analysis. Eur Respir J 2002;20:975.
17. Tsujii M, Kawano S, Tsujii S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705.
18. Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3326.
19. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000;19:19.
20. Murota SI, Morita I, Abe M. The effects of thromboxane B2 and 6-ketoprostaglandin F1α on cultured fibroblast. Biochem Biophys Acta 1997;479:122.
21. Mene P, Abboud HE, Dunn MJ. Regulation of human mesangial cell growth in culture by thromboxane A2 and prostacyclin. Kidney Int 1990;38:232.
22. Dom GW. Role of thromboxane A2 in mitogenesis of vascular smooth muscle cells. Agents Actions 1997;48:43.
23. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2 and specific receptor antagonists on vascular smooth cell proliferation. Circulation 1997;96:2280.
24. Hoper MM, Voelkel NF, Bates TO, et al. Prostaglandins induce vascular endothelial growth factor in human monocytic cell line and rat lung via cAMP. Am J Respir Cell Mol Biol 1997;17:748.
25. Meyer KC, Cardoni A, Xiang ZZ. Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. J Lab Clin Med 2000;135:332.
26. Nakamura T, Kasai K, Banba N, et al. Release of Human Epidermal Growth Factor from Platelets in Accordance with Aggregation in vitro. Endocrinol Jpn 1989;36:23.
27. Kiuru J, Viinikka L, Myllya G, et al. Cytoskeleton-dependent release of human platelet epidermal growth factor. Life Sci 1991;49:1997.